Friday 28 July 2017 The one stop source for free breaking news, expert analysis, and videos on AIM and LSE listed shares


Optiobiotix – Human Study Results – Buy - NEAR TERM target towards 60p

By HotStockRockets | Sunday 4 October 2015


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Optiobiotix (OPTI) last weekreleased the much awaited results of the human trials. Or rather it has not. Mr Market has not twigged this at all. The shares are a buy at 42p or below as we expect them to be heading towards 60p VERY quickly.

The statement reads:

OptiBiotix Health announces it has completed testing and primary data analysis on its capsular food supplement to reduce cholesterol, and commenced pilot manufacturing studies.

The aim of the human study was to establish safety and compliance, and to assess the extent of the lowering potential of its product in this group of volunteers.  Sample testing and primary data analysis has now been completed and in accordance with the option agreement announced in June 2015, the results are being shared with a multinational consumer goods company.

The terms of the option agreement are bound by confidentiality and no further details on the agreement or human studies can be disclosed at this time.

The company also announces it has commenced pilot manufacturing studies to define the scale up requirements to take the strain from laboratory to pilot scale manufacture. These studies are important in determining the best microbial growth conditions to optimise production yields and volumes.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the completion of clinical studies on our capsular food supplement and the sharing of data with our global partner.  The product is now undergoing pilot scale manufacturing studies to maximise production yields and volumes.  This will allow us to progress both the supply and longer term commercial aspects in parallel." 

Ends

That deal, we all know, to be with Proctor & Gamble. If the trial had gone badly P&G would not be taking this further and insisting on confidentiality. That is thus very good news. The fact that Optibiotx is now working on pilot manufacture suggests that the company is close to commercialising and monetizing this product with P&G. And we are talking telephone number potential sales here. Yet Optibiotix is capitalised at just £29 million.

Of course this is just one product, the word is that we will get news on another soon. VERY SOON.

The shares are a buy at up to 42p, the market has read this RNS badly wrong and we expect the stock to be heading towards 60p very soon indeed.

This material first appeared on Hot Stock Rockets when the shares were 40 offer - sorry its paying customers first. Hot Stock Rockets will be serving up its next red hot share tip shortly. To access the UK’s fastest growing share tipping website for less than £5 a month ( or for £5 for one month)   click HERE


Filed under:


Never miss a story.




This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.


More on OPTI


Comments


Enter your comment below. Fields marked * are required. You must preview your comment first before finally posting.




Site by Everywhen